COMP <GO>
REGN vs ABBV // GROSS PROFIT MARGIN
Regeneron Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: REGN 9
— ABBV 5
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
gross-margins
41.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 29.00% | -19.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.2x | 33.3x | -13.10 | REGN | /valuation <GO> |
| Free Cash Flow Yield | 5.14% | 3.47% | +1.67 | REGN | /fcf-yield <GO> |
| Operating Margin | 24.90% | 24.60% | +0.30 | REGN | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 6.90% | +24.50 | REGN | /net-margins <GO> |
| Revenue Growth (YoY) | 1.00% | 8.60% | -7.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 2.27% | -1.83 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.72 | 5.33 | +2.39 | REGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | REGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 72.8 | +6.33 | REGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.15 | +0.01 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 113.1x | -95.70 | REGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $84.30B | $513.86B | -$429.56B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REGN REV | ABBV REV | REGN GROSS % | ABBV GROSS % | REGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | $61.16B | 44.0% | 70.2% | $4.33B | $17.82B |
| FY 2024 | $14.20B | $56.33B | 44.0% | 70.0% | $3.78B | $17.83B |
| FY 2023 | $13.12B | $54.32B | 44.0% | 44.0% | $4.00B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REGN // BETA 1.16
ABBV // BETA 1.15